ONCO, a biotechnology company in its industry and sector, fails key Shariah financial screening criteria due to excessive debt and interest income ratios. The core business in oncology diagnostics is permissible, but financial structure raises significant riba concerns. No inclusion in major Shariah indices confirms non-compliance status. Purification requirements are elevated due to high impure income, and ESG factors show low risk with no controversies. Investors should monitor for financial improvements.